SCHEMBL12296709

SCHEMBL12296709

O=C(O)CCCCCCCCCCCCCCC(=O)NCC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.59
FAAH O00519 4/20 0.58
LMNA P02545 2/20 0.57
PMP22 Q01453 2/20 0.57
TSHR P16473 1/20 0.57
NFKB1 P19838 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
PRMT1 Q99873 1/20 0.52
EPHX2 P34913 2/20 0.51
RECQL P46063 2/20 0.50
KDM4E B2RXH2 2/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
APEX1 P27695 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808624 1.00 PTPN1 (0.59) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL6888800 1.00 PTPN1 (0.59) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL13694070 1.00 PTPN1 (0.59) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL22838868 1.00 PTPN1 (0.59) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL20750809 1.00 PTPN1 (0.59) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL24961509 1.00 PTPN1 (0.59) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL7602768 1.00 PTPN1 (0.59) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL15680097 0.98 PTPN1 (0.56) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL8750020 0.95 PTPN1 (0.63) PTPN1FAAHLMNAPMP22TSHR
SCHEMBL10056657 0.95 PTPN1 (0.63) PTPN1FAAHLMNAPMP22TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000949-A1 SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID NOVO NORDISK AS (DK) 2023-01-05 US disclosed
US-11352406-B2 Insulin derivatives and the medical uses hereof NOVO NORDISK A/S (DK) 2022-06-07 US disclosed
US-20210094999-A1 Novel Acylated Insulin Analogues and Uses Thereof NOVO NORDISK AS (DK) 2021-04-01 US disclosed
US-10570184-B2 GLP-1/glucagon receptor co-agonists for medical use NOVO NORDISK A/S (DK) 2020-02-25 US disclosed
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK AS (DK) 2019-04-18 US disclosed
US-20170101454-A1 GLP-1/Glucagon Receptor Co-Agonists for Medical Use NOVO NORDISK A/S (DK) 2017-04-13 US disclosed
WO-2011117415-A1 NOVEL GLUCAGON ANALOGUES NOVO NORDISK A/S (DK) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170101454-A1 GLP-1/Glucagon Receptor Co-Agonists for Medical Use GLP1R, GCGR, GIPR PTPN1 654/4885FAAH 739/4885LMNA 3923/4885
US-11352406-B2 Insulin derivatives and the medical uses hereof IAPP, INSR, IRS1 PTPN1 1919/4885FAAH 1629/4885LMNA 2035/4885
US-20230000949-A1 SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID PCSK9, EGFR, PCSK6 PTPN1 83/4885FAAH 2825/4885LMNA 2016/4885
US-10570184-B2 GLP-1/glucagon receptor co-agonists for medical use GLP1R, GCGR, GIPR PTPN1 645/4885FAAH 755/4885LMNA 3976/4885
US-20210094999-A1 Novel Acylated Insulin Analogues and Uses Thereof IAPP, GPR119, INSR PTPN1 3051/4885FAAH 491/4885LMNA 2378/4885
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE PTPN1 4022/4885FAAH 179/4885LMNA 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.